SUNHAWK BIO (7759.TWO) stock: key figures, P/E, revenue and dividend
Health Care · Taiwan
SUNHAWK BIO financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Operating income | -101.15 m TWD | -175.37 m TWD |
| EBIT | -86.93 m TWD | -172.21 m TWD |
| Net income | -87.85 m TWD | -172.39 m TWD |
| Diluted EPS – continuing operations | -1.25 TWD | -2.46 TWD |
Full history since 2021, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About SUNHAWK BIO
Sunhawk Vision Biotech, Inc., a drug development company, engages in the research and development of children's myopia eye drops, dry eye drops, and other nucleic acid new drugs for the treatment of ocular surface diseases in Taiwan. The company develops SHJ002 eye drops, which have completed a Phase 2 clinical trial for the treatment of dry eye disease in adult patients and corneal erosion in patients with Sjogren's syndrome, as well as in a Phase 2 clinical trial for myopia control in young children. Sunhawk Vision Biotech, Inc. was founded in 2019 and is based in Taipei, Taiwan.
More stocks
- BLUE DOLPHIN ENERGY CO (BDCO)
- Solana Co (HSDT)
- Chien Shing Harbour Service Co Ltd (8367.TW)
- Hsinli Chemical Industrial (4303.TWO)
- Stealth Group Holdings Ltd (SGI.AX)
- Roots Corp (ROOT.TO)
- PKP Cargo S.A. (PKP.WA)
- Golden State Bancorp (GSBX)
- Braemar Hotels & Resorts Inc. (BHR)
- Canaan Inc (CAN)
- Kenorland Minerals Ltd (KLD.V)
- Oconee Federal Financial Corp (OFED)
Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.